News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene Corporation (CELG) And Galapagos Genomics NV Enter Target Discovery Collaboration


10/19/2005 5:12:14 PM

Celgene (Nasdaq:CELG), a leading global biopharmaceutical company with focus on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and inflammatory disease, and Galapagos, Europe's leading target discovery and adenoviral services company, today announced that they have entered into a multi-year target discovery collaboration.Under the terms of the agreement, Galadeno (Galapagos' wholly owned services unit) will provide Celgene with its adenoviral siRNA and cDNA libraries, SilenceSelect(TM) and FLeXSelect(TM).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES